Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2014

01-02-2014 | Special Article

Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin

Authors: F. Losa, P. Barrios, R. Salazar, J. Torres-Melero, M. Benavides, T. Massuti, I. Ramos, E. Aranda

Published in: Clinical and Translational Oncology | Issue 2/2014

Login to get access

Abstract

Peritoneal carcinomatosis (PC) is a common form of tumour metastasis stemming from gastrointestinal and colorectal cancers. For a long time, PC has been considered a terminal clinical condition treated only with palliative systemic chemotherapy and associated with very limited results. During the last decade, the treatment of advanced colorectal disease has greatly improved with the emergence of new chemotherapy drugs and biological agents. However, the median survival rates still do not surpass 24 months, even though most of these studies correspond to groups of patients with metastatic disease to the liver and/or lung. The approach and development of cytoreductive radical surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) are based on performing radical surgery of the entire visible tumour within the abdomen/peritoneum, followed immediately by HIPEC, which acts upon microscopic tumour that remains present after surgery and which is responsible for the persistence or relapse of peritoneal disease. Peritonectomy procedures are demanding surgical techniques that permit elimination of the tumour present in the peritoneal lining and any other organs and/or structures that are infiltrated. The synergistic effect of hyperthermia and chemotherapy has been well documented. Hyperthermia increases the cytotoxicity of some cytostatic agents and increases the penetration of certain drugs into the neoplastic cells. The prognosis for patients with PC who undergo combined treatment correlates with the volume of PC (tumour burden) measured as the Peritoneal Cancer Index (PCI) and the ability to perform a CRS, to completely eliminate the gross tumour. At least one phase III study and an important number of phase II studies have shown that CRS + HIPEC provides important survival benefits for patients with PC of colorectal origin. The combination of CRS + HIPEC is indicated for patients with good general health, a low PCI, absence of extra-abdominal metastasis and who can, technically, undergo CRS. The early identification of this group of patients, rapid referral to centres specialised in CRS + HIPEC, together with the correct application of this treatment, are key in achieving the best results.
Literature
1.
Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecological malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–7.PubMedCrossRef
2.
Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.PubMedCrossRef
3.
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.PubMedCrossRef
4.
Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414–21.PubMed
5.
Jacquet P, Averbach AM, Stephens AD, Sugarbaker PH. Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy. Dis Colon Rectum. 1995;38:1110–4.PubMedCrossRef
6.
Al-Shammaa HA, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008;14:1159–66.PubMedCrossRef
7.
8.
Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier P, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology. 1994;41:207–13.PubMed
9.
Gómez Portilla A, Cendoya I, López de Tejada I, Olabarría I, Martínez de Lecea C, Magrach L, et al. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update. Rev Esp Enferm Dig. 2005;97:716–37.PubMedCrossRef
10.
Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83–97.PubMed
11.
Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011–9.PubMedCrossRef
12.
Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRef
13.
Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212–22.PubMedCrossRef
14.
Sugarbaker PH. Peritoneum as first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–6.PubMedCrossRef
15.
Elias D, Goéré D. Respectons le Péritoine. C’est notre première ligne de défense contre la carcinose. J Chir. 2007;144:275–6.CrossRef
16.
Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MBL, Cellerino R, et al. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil based regimens. Am J Clin Oncol. 2002;25:140–8.PubMedCrossRef
17.
Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 1992; 10:896–03.
18.
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMed
19.
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.PubMedCrossRef
20.
Douillard JY, Cunningham D, Roth AD, Navarro M, Karasek P, Jandik P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicenter randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRef
21.
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.PubMedCrossRef
22.
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–705.PubMedCrossRef
23.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef
24.
Goldberg RM, Sargent DJ, Morton RE, Fuchs ChS, Ramanatham RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.PubMedCrossRef
25.
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.PubMedCrossRef
26.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.PubMedCrossRef
27.
Tentes AA. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29:69–73.PubMedCrossRef
28.
Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;35:413–9.PubMedCrossRef
29.
Sebbag G, Sugarbaker PH. Peritonal mesothelioma proposal for a staging system. Eur J Surg Oncol. 2001;27:223–4.PubMedCrossRef
30.
Yonemura Y, Nojima N, Kawamura T, Kim BS, Fujita H, Nozaki S. Mechanisms of the formation of peritoneal dissemination. Peritoneal dissemination. Kanazawa: Maeda Shoten; 1998. p. 1–46.
31.
Sobin LH, Gospodarowicz MK, Wittekind Ch, International Union Against Cancer, editors. TNM Classification of Malignant Tumors, 7th edn. Chichester-Hoboken: Wiley-Blackwell; 2010.
32.
Sugarbaker PH. Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. In: A manual for physicians and nurses, 3rd edn. Grand Rapids, Michigan: The Ludann Company; 1998.
33.
Yan TD, Sim J, Morris DL. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:1807–17.PubMedCrossRef
34.
Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93:1270–6.PubMedCrossRef
35.
Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240:278–85.PubMedCrossRef
36.
Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.PubMedCrossRef
37.
Moran BJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health. 2006;28:375–8.CrossRef
38.
Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14:2270–80.PubMedCrossRef
39.
Smeenk RM, Verwaal VJ, Zoermulder ZA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408–14.PubMedCrossRef
40.
Stewart JH 4th, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol. 2005;12:765–77.PubMedCrossRef
41.
Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J. 2009;15:196–9.PubMedCrossRef
42.
Barrios P, Roqué M, Lozano JM, Ramos I, Bianchi A, Bonfill X. Revisión sistemática del tratamiento combinado multidisciplinar en las enfermedades malignas del peritoneo. Citorreducción quirúrgica radical + quimioterapia intraperitoneal ± hipertermia (técnica de Sugarbaker). Informes de Evaluación de Tecnologías Sanitarias, AATRM núm. 2007/19. Madrid: Plan de Calidad para el Sistema Nacional de Salud, Ministerio de Sanidad y Política Social, Agència d’Avaluació de Tecnologia i Recerca Mèdiques de Cataluña; 2009.
43.
Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRef
44.
Hansson J, Graf W, Påhlman L, Nygren P, Mahteme H. Postoperative adverse events and long –term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2009;35:202–8.PubMedCrossRef
45.
Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54:293–9.PubMedCrossRef
46.
Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2005;12:910–8.PubMedCrossRef
47.
Gomes da Silva R, Sugarbaker P. Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Am J Coll Surg. 2006;203:878–86.CrossRef
48.
Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res. 2007;13:1232–7.PubMedCrossRef
49.
Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10:112–22.PubMedCrossRef
50.
Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinectics, tissue distribution and tolerance. Ann Oncol. 2004;15:1558–65.PubMedCrossRef
51.
Elias D, Ouellet JF. Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am. 2001;10:915–33.PubMed
52.
Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.PubMedCrossRef
53.
Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703–8.PubMedCrossRef
54.
Van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res. 2003;23:1501–8.PubMed
55.
Flessner M, Henegar J, Bigler S, Genous L. Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit Dial Int. 2003;23:542–9.PubMed
56.
De Lima Vázquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52:108–12.PubMedCrossRef
57.
Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113:631–6.PubMed
58.
Glehen O, Cotte E, Brigand C, Arvieux C, Sayag-Beaujard AC, Gilly FN. Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy. Rev Med Int. 2006;27:382–91.CrossRef
59.
Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuos hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. 1984;44:1840–2.PubMed
60.
Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgoulias V, et al. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol. 2007;14:1220–8.PubMedCrossRef
61.
Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.PubMedCrossRef
62.
Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463–8.PubMedCrossRef
63.
Van der Speeten K, Stuart OA. Sugarbaker PH. Pharmacokinetics and pharmacodynamics or perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15:216–24.PubMedCrossRef
64.
Barrios P, Ramos I, Escayola C, Martin M. Implementación y desarrollo de un programa de tratamiento de la carcinomatosis peritoneal en Cataluña. Indicaciones y resultados clínicos con la técnica de Sugarbaker, 1st edn. Barcelona: Agència d’Avaluació de Tecnologia i Recerca Mèdiques; 2009.
65.
Nygren P, Fridborg H, Csoka K, Sundström C, De la Torre M, Kristensen J, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer. 1994;56:715–20.PubMedCrossRef
66.
Mahteme H, Von Heideman A, Grundmark B, Tholander B, Pahlman L, Glimelius B, et al. Heterogeneous activity of cytotoxic drugs in patients samples of peritoneal carcinomatosis. Eur J Surg Oncol. 2008;34:547–52.PubMedCrossRef
67.
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chem Pharmacol. 1999;43:15–25.CrossRef
68.
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRef
69.
Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–21.PubMedCrossRef
70.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.PubMedCrossRef
71.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
72.
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef
73.
Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.PubMedCrossRef
74.
Elias D, Sideris L, Pocard M, Edè C. Ben Hassouna D, Ducreux M, et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol. 2004;15:781–5.PubMedCrossRef
75.
Gomez-Portilla A, Kusamura S, Baratti D, Deracco M. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98:228–31.CrossRef
76.
Pelz JO, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689–701.PubMedCentralPubMedCrossRef
77.
Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cáncer. Eur J Surg Oncol. 2006;32:632–6.PubMedCrossRef
78.
Hadi R, Saunders V, Utkina O, Clingan P, Kam P, Links M, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg. 2006;76:156–61.PubMedCrossRef
79.
Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after complete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818–24.PubMedCrossRef
80.
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef
81.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.PubMedCentralPubMedCrossRef
82.
Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004;14:35–41.PubMedCrossRef
83.
Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.PubMedCrossRef
84.
Quénet F, Elias D. (principal investigators): Protocole Prodige 7. ACCORD 15/0608. EndraCT N: 2006-006175-20. Essai de phase III évaluant la place de la chimiohyperthermie intrapéritonéale peropéraroire (CHIP) après résection maximale d’une carcinose péritonéale d’origine colorectale associée à une chimiothérapie sysstémique. FNCLCC; 2006.
85.
Casado-Adam A, Alderman R, Stuart OA, Chang D, Sugarbaker PH. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011;2011:1–10.CrossRef
86.
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.PubMed
87.
McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73.PubMedCrossRef
88.
McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62.PubMedCrossRef
89.
Yan TD. Peritoneal carcinomatosis of colorectal origin: standard of care. Ann Surg. 2006;244:632–3.PubMedCrossRef
90.
Cao T, Yan T, Black D, Morris D. Systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152–65.PubMedCrossRef
91.
Baratti D, Kusamura S, Deraco M. The fifth international workshop on peritoneal surface malignancy (Milan, Italy, December 4–6, 2006): methodology of disease-specific consensus. J Surg Oncol. 2008;98:258–62.PubMedCrossRef
92.
National Institute for Health and Clinical Excellence (UK). Cytoreduction Surgery Followed by Hyperthermic Intraoperative Peritoneal Chemotherapy for Peritoneal Carcinomatosis. London: NICE; 2010.
93.
Aranda E, Abad A, Carrato A, Cervantes A, Garcia-Foncillas J, Garcia Alonso P. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol. 2011;13:162–78.PubMedCrossRef
Metadata
Title
Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin
Authors
F. Losa
P. Barrios
R. Salazar
J. Torres-Melero
M. Benavides
T. Massuti
I. Ramos
E. Aranda
Publication date
01-02-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1053-x

Other articles of this Issue 2/2014

Clinical and Translational Oncology 2/2014 Go to the issue

Research Article

Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer

Research Article

Impact of machines on plan quality: volumetric modulated arc therapy and intensity modulated radiation therapy

Research Article

What is the future burden of HPV-related cancers in Spain?

Research Article

MCAM expression is associated with poor prognosis in non-small cell lung cancer

Research Article

Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy

Research Article

Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits